Oncocyte to Participate at Upcoming Investor Conferences
August 03 2022 - 4:01PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company with the mission to improve patient outcomes by providing
personalized insights that inform critical decisions throughout the
patient care journey, announced today that its management team will
participate at the following conferences:
- UBS Genomics 2.0
and MedTech Innovations SummitPresenting on Thursday, August 11,
2022 at 5:00 p.m. Eastern Time in Dana Point, California. The live
audio webcast and replay of the presentation may be accessed for
180 days on the “Investors” section of the company’s website at
https://oncocyte.com/.
- 7th Annual
Needham Virtual Med Tech & Diagnostics 1x1 Conference
Participating on Monday, August 15, 2022
About OncocyteOncocyte is a precision
diagnostics company with a mission to improve patient outcomes by
providing personalized insights that inform critical decisions
throughout the patient care journey.
Through its proprietary tests and pharmaceutical services
business, the Company aims to help save lives by accelerating the
diagnosis of cancer and advancing cancer care. The Company’s tests
are designed to help provide clarity and confidence to physicians
and their patients at every stage. DetermaRx™ identifies
early-stage lung cancer patients who are at high risk for cancer
recurrence and who may benefit from adjuvant chemotherapy.
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies. The
Company’s pipeline of tests in development also includes
DetermaTx™, which will assess mutational status of a tumor,
DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term
recurrence monitoring test, and VitaGraft™, a blood-based solid
organ transplantation monitoring test. In addition, Oncocyte’s
pharmaceutical services provide companies that are developing new
cancer treatments a full suite of molecular testing services to
support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and
VitaGraft™ are trademarks of Oncocyte Corporation.
Investor ContactCaroline CornerICR
Westwicke(415) 202-5678caroline.corner@westwicke.com
Media ContactMegan KernanICR Westwicke
Healthcare PRTel: 646.677.1870Megan.kernan@westwicke.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Sep 2023 to Sep 2024